Recombinant factor VIIa in massive postpartum haemorrhage.
Massive postpartum haemorrhage is a major cause of maternal and fetal morbidity and mortality. Management mainstays include transfusion therapy, uterotonic agents and surgery. The "off label" use of recombinant activated factor VII appears to have an evolving role in the management of massive postpartum haemorrhage refractory to conventional treatments. The current literature is reviewed.
Karalapillai
D
D
Department of Anaesthesia, Royal Women's Hospital, Carlton, Victoria, Australia.
Popham
P
P
D003029:Coagulants / Q000009:adverse effects / Q000627:therapeutic use*; D005167:Factor VII / Q000009:adverse effects / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D033221:Jehovah's Witnesses; D013513:Obstetric Surgical Procedures / Q000009:adverse effects; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D014593:Uterine Inertia / Q000188:drug therapy
D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa